Lebrikizumab: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Lebrikizumab. Educational only — not medical advice.
Labeled uses
EBGLYSS is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and pediatric patients 12 years of age and older who weigh at least 40 kg whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. EBGLYSS can be used with or without topical corticosteroids.
Source: FDA labeling via NIH DailyMed (set 7a774ea2…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.